U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284472) titled 'Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia' on Nov. 27.
Brief Summary: The goal of this clinical trial is to learn if the investigational drugs EXV-802 and EXV-801 can safely and effectively reduce agitation in participants with Alzheimer's Disease Dementia.
Researchers will compare EXV-802 and EXV-801 with a placebo to see if EXV-802 and/or EXV-801 reduces agitation more effectively than the placebo.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Agitation Associated With Alzheimer's Disease Dementia
Intervention:
DRUG: EXV-802
Specified dose ...